Takeda Pharmaceutical Co. Ltd. - Research and Development

Takeda Pharmaceutical Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Research-and-Development" stands at 691.57 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2023.

Takeda Pharmaceutical Co. Ltd.'s second quarter result of 161.48 Billion JPY for the item "Research and Development" represents an increase of 12.23 percent compared to it's first quarter result.

Also, Takeda Pharmaceutical Co. Ltd.'s second quarter result of 161.48 Billion JPY for the item "Research and Development" represents a decrease of -8.02 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Takeda Pharmaceutical Co. Ltd.'s second quarter result of 691.57 Billion JPY for the item "Research and Development" represents a decrease of -2.00 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -4.91 percent compared to the value the year prior.
The 1 year change in percent is -4.91.
The 3 year change in percent is 21.38.
The 5 year change in percent is 43.57.
The 10 year change in percent is 78.72.

The Serie's long term average value is 440.38 Billion Japanese Yens. It's latest available value, on 09/30/2025, is 57.04 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2011, to it's latest available value, on 09/30/2025, is +264.49%.
The Serie's change in percent from it's maximum value, on 06/30/2024, to it's latest available value, on 09/30/2025, is -5.99%.